Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Zhongjiefeng tablet** is an oral traditional Chinese medicine tablet prepared from *Sarcandra glabra* whole-herb material, known in Chinese materia medica as zhongjiefeng or Sarcandrae Herba. It is a single-botanical pharmaceutical product used in China for inflammatory and infectious conditions classified in traditional medicine as heat-toxin accumulation, including pneumonia, appendicitis, and cellulitis, and as adjunctive treatment in cancer. Its product-specific molecular mechanism has not been established; the botanical contains multiple constituents, including coumarins, phenolic acids, flavonoids, sesquiterpenes, and polysaccharides, with reported preclinical anti-inflammatory, antimicrobial, and immunomodulatory activity. A ChiCTR-registered study is evaluating zhongjiefeng tablet for prevention and treatment of multidrug-resistant *Pseudomonas aeruginosa* infection at tracheostomy sites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhongjiefeng tablet.